309/5: 00 Meta - analysis of rare and common
exome chip variants identifies and replicates S1PR4 and other novel genes influencing blood cell traits.
299/4: 30 Large - scale
exome chip association analysis identifies novel type 2 diabetes susceptibility loci and highlights candidate effector genes.
A fundamental weakness of
exome chip designs (and exome sequencing, for that matter) is the emphasis of known genes.
Notably, that GWAS was conducted using a custom high - throughput SNP array with classic GWAS variants (tag SNPs), a catalog of known protein - altering variants (
exome chip) and several custom sets based on prior studies of AMD:
Not exact matches
We prepare and normalize libraries for RNA - seq, miRNA - seq, DNA - Seq,
ChIP - seq, targeted
exome sequencing, amplicon sequencing, bacterial 16S metagenomics and whole genome sequencing.
Bioinformatics services include data QC, outlier detection and general data management, and data analysis from platforms including Illumina or Affymetrix microarrays, RNA - Seq, SNP arrays,
Exome - sequencing,
ChIP - chips and CHIP -
ChIP -
chips and
CHIP -
CHIP - seq.
These technologies include next generation
exome and whole - genome sequencing,
ChiP - sequencing, tissue transcriptome and epitope profiling, and miRNome, proteome and metabolome screening in different body fluids.
With this technology, we sequence DNA, RNA, micro-RNAs and perform
ChIP - Seq and whole
exome sequencing.
We have in - house computational pipelines built for metagenomic viral discovery, RNASeq quantification,
exome sequencing and whole genome sequencing for variants detection using GATK, Affymetrix & Illumina expression array and SNP
chips, GWAS, digital PCR analysis, mass spectrometry and biomarker discovery.
Their defined «
exome» was 30 Mb, which they targeted using two solid - phase array capture
chips.
Methods: We used whole -
exome sequencing to detect the presence of
CHIP in peripheral - blood cells and associated such presence with coronary heart disease using samples from four case - control studies that together enrolled 4726 participants with coronary heart disease and 3529 controls.